Oct 2, 2026, 6:30 AM EDT · 10 days ago Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 30, 2026, 6:30 AM EDT · 12 days ago Compass Pathways Appoints Kelley Boucher as Chief People Officer
Sep 16, 2026, 6:30 AM EDT · 26 days ago Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Sep 15, 2026, 6:30 AM EDT · 27 days ago Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
2026-09-11T20:15:10.000Z · 4 weeks ago Strata Mental Health Solutions awarded training grant by Compass Pathways
Sep 11, 2026, 4:10 PM EDT · 4 weeks ago Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
Sep 10, 2026, 8:00 AM EDT · 4 weeks ago Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Sep 10, 2026, 6:35 AM EDT · 4 weeks ago Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Sep 10, 2026, 6:30 AM EDT · 4 weeks ago Compass Pathways to Participate in Investor Conferences the Week of September 14th
Sep 9, 2026, 4:40 PM EDT · 4 weeks ago Compass Pathways Forecast: Breakout Could Target $22.51–$25.51
2026-09-09T10:35:53.000Z · 4 weeks ago Compass Pathways reports 52-week results from Phase 3 COMP005 trial
Sep 9, 2026, 6:30 AM EDT · 4 weeks ago Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Sep 8, 2026, 6:30 AM EDT · 4 weeks ago Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Sep 2, 2026, 6:30 AM EDT · 5 weeks ago Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Sep 1, 2026, 6:30 AM EDT · 5 weeks ago Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
2026-08-07T10:10:38.000Z · 2 months ago Compass Pathways price target lowered to $65 from $70 at H.C. Wainwright
2026-08-06T15:50:56.000Z · 2 months ago Compass Pathways price target raised to $18 from $17 at Morgan Stanley
2026-08-06T14:26:07.000Z · 2 months ago Psychedelic: Compass Pathways, GH Research report quarterly earnings CMND ENVB GHRS HELP
2026-08-06T13:38:16.000Z · 2 months ago Compass Pathways price target raised to $22 from $17 at B. Riley
Aug 6, 2026, 7:00 AM EDT · 2 months ago Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
2026-08-06T10:54:31.000Z · 2 months ago Compass Pathways price target lowered to $21 from $22 at RBC Capital
Aug 6, 2026, 6:30 AM EDT · 2 months ago Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
2026-08-05T10:46:08.000Z · 2 months ago Compass Pathways current cash position sufficient throughout 2028
Aug 5, 2026, 6:30 AM EDT · 2 months ago Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Jul 29, 2026, 6:30 AM EDT · 2 months ago Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
2026-07-27T09:25:06.000Z · 2 months ago Compass Pathways initiated with an Equal Weight at Wells Fargo
2026-07-17T18:15:10.000Z · 2 months ago COMPASS Pathways PLC put volume heavy and directionally bearish
2026-07-16T10:40:21.000Z · 2 months ago Compass Pathways’ COMP360 treatment featured in published PTSD trial
Jul 16, 2026, 6:35 AM EDT · 2 months ago Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
Jul 7, 2026, 6:30 AM EDT · 3 months ago Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
Jun 26, 2026, 9:30 AM EDT · 3 months ago A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year DFTX
May 31, 2026, 8:00 AM EDT · 4 months ago Why Trump reversed course to fast-track psychedelic drugs for mental healthcare
May 28, 2026, 6:30 AM EDT · 4 months ago Compass Pathways Elects Kathleen Tregoning to Board of Directors
May 26, 2026, 6:30 AM EDT · 4 months ago Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
May 14, 2026, 6:30 AM EDT · 5 months ago Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
May 13, 2026, 6:30 AM EDT · 5 months ago Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
May 6, 2026, 6:30 AM EDT · 5 months ago Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Apr 24, 2026, 10:37 AM EDT · 5 months ago Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
Apr 21, 2026, 6:30 AM EDT · 5 months ago Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
Apr 20, 2026, 2:05 PM EDT · 5 months ago How Trump's psychedelics executive order could unlock stalled cannabis reform ATAI DFTX HELP GHRS
Apr 20, 2026, 10:45 AM EDT · 5 months ago Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research ATAI DFTX GHRS
Apr 20, 2026, 8:26 AM EDT · 5 months ago Psychedelic stocks rally with Trump's support ATAI DFTX GHRS
Apr 20, 2026, 8:18 AM EDT · 5 months ago Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. ATAI GHRS DFTX
Apr 20, 2026, 6:43 AM EDT · 5 months ago Psychedelic drug makers rally as Trump orders FDA to expedite reviews ATAI DFTX ENVB GHRS HELP
Apr 20, 2026, 6:30 AM EDT · 5 months ago Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Apr 18, 2026, 4:12 PM EDT · 5 months ago Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
Apr 14, 2026, 6:30 AM EDT · 6 months ago Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
Apr 8, 2026, 6:30 AM EDT · 6 months ago Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
Mar 24, 2026, 7:30 AM EDT · 6 months ago Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
Mar 12, 2026, 6:30 AM EDT · 7 months ago Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
Feb 26, 2026, 6:30 AM EST · 7 months ago Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
Feb 24, 2026, 6:39 AM EST · 7 months ago Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
Feb 18, 2026, 8:18 PM EST · 7 months ago Compass Pathways Announces Pricing of $150 Million Public Offering
Feb 17, 2026, 4:06 PM EST · 7 months ago Compass Pathways Launches Proposed $150.0 Million Public Offering
Feb 17, 2026, 6:42 AM EST · 7 months ago Compass Pathways' depression treatment meets main goal in late‑stage study
Feb 17, 2026, 6:30 AM EST · 7 months ago Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Feb 16, 2026, 8:00 AM EST · 7 months ago Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
Feb 9, 2026, 5:01 PM EST · 8 months ago COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure
Jan 7, 2026, 6:30 AM EST · 9 months ago Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD